Abstract 2494
Background
CAR-T cells are a new cancer treatment, where T cells are taken from the patient and modified in a laboratory to target cancer cells. There have been some promising results from early clinical trials, which have led to two products being made available to patients in the NHS. Axicabtagene ciloleucel for relapsed/refractory B-cell lymphoma patients and tisagenlecleucel for relapsed/refractory B-cell lymphoma patients and relapsed/refractory B-ALL patients under the age of 25. There are multiple clinical trials in progress throughout Europe, mostly in the haematology setting, with some in oncology. There are significant toxicities to this treatment modality and this is a complex heavily pre-treated patient population. Education of the wider nursing and multi professional team is therefore crucial. A new Lecturer Practitioner role was established, to focus on CAR-T. This poster explores nurses’ learning needs associated with introducing CAR-T therapy in a specialist cancer hospital in London, UK.
Methods
Data has been collected through evaluation of previous nursing educational initiatives in CAR-T therapy, which aimed to identify further learning needs. Further data collection is in development.
Results
Although this work is on-going, initial findings indicate that nurses require more education and support particularly around managing toxicities and patient expectations. Challenges for educating nurses also include uncertainties around the long-term effects of this treatment modality.
Conclusions
CAR-T therapy is being implemented at multiple centres throughout the UK/Europe and it is evident that there are a multitude of future opportunities for career development for nurses in this area. The role of a Lecturer Practitioner in CAR-T at a specialist cancer hospital has been created to address some of the educational needs of the nursing and multi-professional team. The post holder is involved in a wide range of educational initiatives, from national bespoke study days and academic cancer care modules to ward based teaching. It is clear that there is a need for a role that combines clinical practice and academia, bridging the theory to practice gap and providing expert clinical knowledge to nurses caring for these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
R. Ellard: Honoraria (self): MolMed; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Kite Gilead. All other authors have declared no conflicts of interest.
Resources from the same session
1885 - Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: an open label, non randomized study
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
5259 - Integrative RNAseq and Target panel sequencing reveals common and distinct innate and adaptive resistance mechanisms to BRAF inhibitors
Presenter: Phil Cheng
Session: Poster Display session 3
Resources:
Abstract
5619 - Effective treatment with T-VEC monotherapy in Stage IIIB/C-IVM1a Melanoma of the Head & Neck Region
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
5666 - Re-introduction of T-VEC Monotherapy in Recurrent Stage IIIB/C-IVM1a melanoma is effective
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
4117 - Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): subgroup analysis of the phase 3 OPTiM study
Presenter: Mark Middleton
Session: Poster Display session 3
Resources:
Abstract
5303 - Real Life Use of Talimogene Laherparepvec in Melanoma in Centers in Austria and Switzeland
Presenter: Christoph Hoeller
Session: Poster Display session 3
Resources:
Abstract
4130 - Outcomes of advanced melanoma patients who discontinued pembrolizumab (pembro) after complete response (CR) in the French early access program (EAP)
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
2050 - Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)
Presenter: Sarah Knispel
Session: Poster Display session 3
Resources:
Abstract
1618 - Comparative-Effectiveness of Pembrolizumab vs. Nivolumab for Patients with Metastatic Melanoma
Presenter: Justin Moser
Session: Poster Display session 3
Resources:
Abstract
3556 - Long-term efficacy of combination nivolumab and ipilimumab for first-line treatment of advanced melanoma: a network meta-analysis
Presenter: Peter Mohr
Session: Poster Display session 3
Resources:
Abstract